HK40056245B - Solid dispersion of 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide - Google Patents

Description

Solid dispersions of 6- (1-propenylpiperidin-4-yl) -2- (4-phenoxyphenyl) niacinamide

The present invention relates to solid dispersions of 6- (1-propenylpiperidin-4-yl) -2- (4-phenoxyphenyl) niacinamide.

Background

6- (1-Acylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide (Compound I) is a substituted nicotinamide Bruton Tyrosine Kinase (BTK) inhibitor. The preparation of compound I and its use in the treatment of cancer, inflammation and autoimmune diseases is described in WO2015/028662, which is incorporated herein by reference in its entirety.

Drawings

Fig. 1 shows the dissolution behavior of form a, form F and HPMCAS-20-SDD (ASD prepared with spray drying with 20% drug loading).

FIG. 2 is an XRPD for HPMCAS-20-SDD.

FIG. 3 shows dissolution behavior of HPMCAS-20-SDD, HPMCAS-40-SDD, HPMCAS-60-SDD and PVPVA-20-HME.

FIG. 4 is the pharmacokinetics of HPMCAS-20-SDD and HPMCAS-40-SDD: three fed female Sprague Dawley rats were orally administered 10 ml of a 0.5% methylcellulose suspension with SDD at a dose of 30 milligrams per kilogram.

Fig. 5 shows XRD patterns of ASD after one week of storage under various conditions: (a) PVPVA-20-HME; (B) HMPCAS-20-SDD; (C) HMPCAS-40-SDD; (D) HMPCAS-60-SDD.

FIG. 6 is a dissolution profile of HMPCAS-20-SDD in FaSSIB after 0-58 days of storage under the following conditions: (a) 25 ℃/60% rh, opening; (B) 25 ℃/60% RH, sealing; (C) 40 ℃/75% RH, sealing.

FIG. 7 shows the dissolution behavior of HMPCAS-20-SDD tablets before and after storage for one month at 25 ℃ +60% relative humidity.

Detailed description of the invention

The present invention relates to solid dispersions (ASD) comprising 6- (1-propenylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide (compound I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable polymer.

The inventors have found that the ASD form of compound I is more advantageous than the crystalline form for use in the preparation of pharmaceutical formulations. The ASD form of compound I has good bioavailability, good solubility, good dissolution, and is chemically and physically stable.

Crystal form A

Form a was prepared from starting compound I as described in WO 2015/048662. The starting compound I was dissolved in methylene chloride and precipitated with ethyl acetate to give form A.

X-ray powder diffraction (XRPD) data for form a are shown in table 1.

TABLE 1

2theta	d interval	Intensity (%)
			5.39	16.41	100.00
8.41	10.51	77.19
			10.11	8.75	19.53
11.06	8.00	15.79
			13.23	6.69	17.33
13.64	6.49	4.27
			14.29	6.20	9.80
16.08	5.51	27.72
			16.35	5.42	21.31
17.71	5.01	13.12
			18.69	4.75	64.74
19.14	4.64	43.60
			21.02	4.23	16.01
21.85	4.07	22.24
			23.25	3.83	8.69
23.61	3.77	7.55
			25.25	3.53	5.99
26.82	3.32	4.31
			29.59	3.02	3.00

The solubility of the crystal form A of the invention after 24 hours of equilibration in water at room temperature is 0.013mg/mL.

Crystal form F

Form F can be prepared from form a by slurrying in a solvent or solvent mixture (e.g., methanol, ethanol, acetonitrile, methanol/water or ethanol/water).

XRPD data for form F are shown in table 2.

TABLE 2

/>

Form F is anhydrate.

The solubility of form F of the present invention after 24 hours equilibration in water at room temperature was 0.004mg/mL.

Form F is a stable form that can be used as an Active Pharmaceutical Ingredient (API) in a pharmaceutical formulation. However, it is slow to dissolve and has low bioavailability (20%).

Solid dispersion

The ASD form of compound I consists of compound I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable polymer. The ASD form of compound I is stable in solid state for long term and can be used for preparing pharmaceutical preparations. The ASD form of the compound I has ideal drug property and is suitable for production.

Pharmaceutically acceptable salts of compound I suitable for use in the ASD of the present invention are conventional non-toxic salts including salts formed with inorganic acids (such as hydrochloride, bromate, sulfate, phosphate, etc.), salts of organic carboxylic or sulfonic acids (such as formate, acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, p-methanesulfonate, etc.), or salts of acidic amino acids (such as aspartic acid, isoglutamic acid, etc.).

Pharmaceutically acceptable polymers are used in ASD to stabilize the compounds and dispersions and may be hydrophilic carrier polymers including cellulose-based polymers such as hydroxypropyl methylcellulose (HPMC), ethylcellulose, hydroxyethyl cellulose, hydroxyethyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalate (HPMCP), cellulose acetate phthalate, methylcellulose, cellulose, carboxymethyl cellulose, microcrystalline cellulose, silicified microcrystalline cellulose, and the like, starch-based polymers such as hydroxypropyl starch, starch (including fully pregelatinized and semi-pregelatinized starches derived from corn, potato, rice, wheat, and the like), polyethylene glycol, polyacrylic acid, polyacrylamide, polyethylene oxide, polyvinylpyrrolidone, polyvinyl alcohol, polyglycolic acid glyceride, polymethyl methacrylate, hydrophilic colloids such as carrageenan, chitosan, alginic acid, hyaluronic acid, pectic acid, and the like.

Preferred polymers of the present invention include hydroxypropyl methylcellulose acetate succinate (HPMC-AS), polyvinylpyrrolidone-vinyl acetate copolymer (PVP-VA), polyvinylpyrrolidone (PVP) and hydroxypropyl methylcellulose (HPMC). More preferred are HPMC-AS and PVP-VA.

The amount of compound I in the ASD is typically 10-60%, or 10-50%, 10-40%, 15-50%, or 15-45% by weight. For example, the content (drug loading) of compound I in the ASD is 20% or 40% by weight.

The weight ratio of compound I to pharmaceutically acceptable polymer (such AS HPMC-AS or PVP-VA) is generally between 1:1 and 1:10 or 1:1 and 1:4.

For example, the ASD form of compound I consists of 20-40% w/w compound I and 60-80% w/w HPMC-AS.

For example, the ASD form of Compound I consists of 20-40% w/w of Compound I and 60-80% w/w PVP-VA.

In a preferred embodiment, the ASD of the present invention does not comprise any surfactant.

In another embodiment, the ASD of the present invention may comprise surfactants to enhance solubility and/or to improve physical stability. The surfactant will generally comprise 5-40% w/w of the ASD, preferably 10-30% w/w. Pharmaceutically acceptable surfactants that may be used as additives in the solid dispersion may include polysorbates (such as polysorbate 20, polysorbate 40, polysorbate 80, polysorbate 85, polysorbate 60, etc.), cyclodextrins, polyoxyl 20 stearates, polyoxyl 35 castor oil, poloxamers, polyoxyethylene sorbitol monostearate, polyethylene glycol 40 sorbitol distearate, polyoxyl 40 hydrogenated castor oil, poloxamer 331, polyoxyethylene fatty acid esters, polyoxyl 40 castor oil, poloxamer 188, polyoxyethylene polyoxypropylene 1800, oleic acid, sodium deoxycholate, sodium dodecyl sulfate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan trioleate, N-carbamoylmethoxypolyethylene glycol 2000-1, 2-distearate, myristic acid, emulsifier, stearic acid, polyoxyl 40 stearate, polyoxyl 60 stearate, sucrose stearate, tocopherol, polyoxyl castor oil, synthetic triglycerides, trimyristate, glyceryl tristearate, magnesium stearate, lecithin, dodecyl sulfate, vitamin E, egg yolk phospholipids, sodium succinyl, dimyristoylphospholipid glycerol, dimyristoylphospholipid, capryol 90 (propylene glycol monocaprylate), capryol PGMC (propylene glycol monocaprylate), deoxycholate, cholesterol, cremophor EL, propylene glycol alginate, croval A-10 (PEG 60 almond glyceride), labrafil 1944 (oleoyl polyethylene glycol-6 glyceride), labrafil 2125 (linoleoyl polyethylene glycol-6 glyceride), labrasol (octanoyl hexanoyl polyethylene glycol-8 glyceride), laurogol 90 (propylene glycol monolaurate), laurogol FCC (propylene glycol laurate), calcium stearate, mortise phospholipid Centromix E, mortise phospholipid Centrophase 152,Lecithin Centrol3F21B,POE 26 glycerol, olepal isosteariques (PEG-6 isostearate), plurol diisostearique (polyglyceryl-3-diisostearate), plurol Oleique CC, 20 sorbitan trioleate, tagat TO (polyoxyethylene glycerol trioleate) or Solutol (polyethylene glycol-15 hydroxystearate), or mixtures thereof. Preferred surfactants are polysorbates and beta-cyclodextrins.

The thermochemical properties of ASD can be analyzed by Differential Scanning Calorimeter (DSC). The results showed that the ASD of compound I had only one glass transition temperature and no other endothermic peak (melting peak), confirming that compound I was amorphous in the ASD. The obtained ASD can be used for preparing pharmaceutical composition with high bioavailability.

The ASD of the present invention has better dissolution in fasted state simulated intestinal fluid than form A, and form A has better dissolution than form F.

The ASD of the present invention is stable and remains amorphous for at least one week at 25-40 ℃ and 60-75% relative humidity.

In one embodiment, the ASD of the present invention is chemically stable with less than 5% degradation for at least one year when stored at 25 ℃ and 60% relative humidity.

Process for preparing ASD

The ASD of the present invention may be prepared by spray drying, hot melt extrusion or lyophilization techniques.

The compound I is finely dispersed in a solid matrix (molecular dispersion) such that dissolution of the compound is maximized, thereby improving bioavailability of the compound.

In one embodiment, the ASD of the present invention may be obtained by dissolving compound I in a sufficient amount of an organic solvent and mixing the resulting solution with a solution comprising a pharmaceutically acceptable polymer and optionally a solubilizing agent, such as a surfactant, to obtain a spray solution. The solvent may then be evaporated to disperse/dissolve the drug in the matrix.

In one embodiment, the method comprises the steps of: (a) Dissolving compound I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable polymer in a solvent; (b) drying the solution of step (a).

In one embodiment, step (a) comprises: dissolving compound I in a sufficient amount of an organic solvent; dissolving a pharmaceutically acceptable polymer in a solvent; the two solutions were mixed.

In one embodiment, an organic solvent may be used to dissolve compound I and the polymer. The organic solvent may include an alcohol, an alkyl halide, acetone, acetic acid, ethyl acetate, N-dimethylformamide, DMSO, tetrahydrofuran, or mixtures thereof. For example, the alcohol is methanol, ethanol, propanol or isopropanol. For example, the haloalkane is dichloromethane, chloroform or carbon tetrachloride.

In one embodiment, water or a mixture of water and an organic solvent is used to dissolve compound I and the polymer.

In one embodiment, step (b) comprises spray drying. In another embodiment, step (b) comprises spray drying in combination with a fluidized bed. In a further embodiment, step (b) comprises evaporating the solvent using a rotary evaporator.

In one embodiment, the solvent may be removed by spray drying techniques. The term "spray drying" is generally used and broadly refers to a process that involves breaking up a liquid mixture into small droplets (atomization) and rapidly removing solvent from the mixture in a spray drying apparatus (e.g., a nozzle) that can forcefully evaporate the solvent in the droplets. In a typical spray drying process, the feed liquid may be a solution, slurry, emulsion, gel or paste, provided that it is pumpable and capable of being atomized.

The spray drying method and spray drying apparatus are generally described in Perry's handbook of chemical engineers, pages 20-54 to 20-57 (sixth edition 1984). The driving force for solvent removal or evaporation is typically provided by maintaining the partial pressure of the solvent in the spray drying apparatus well below the vapor pressure of the solvent at the temperature of the dried droplets.

After spraying is completed, the feeding and atomizing are stopped, and the resulting solid dispersion is collected and, if necessary, further dried in an oven at about 40-60 ℃.

In one embodiment, the ASD is prepared by hot melt extrusion. In this process, compound I and the polymer are first homogeneously mixed. The mixture was fed into an extruder and extruded at a temperature exceeding 100 ℃. The collected solids were ground and passed through a mesh filter to give ASD powder.

Pharmaceutical composition

The invention also relates to a pharmaceutical composition in solid form comprising an effective dose of compound I in ASD form and a pharmaceutically acceptable carrier.

Pharmaceutically acceptable carriers are inactive ingredients and can be selected by those skilled in the art with conventional criteria. Pharmaceutically acceptable carriers include, but are not limited to, non-aqueous solutions, suspensions, emulsions, microemulsions, micellar solutions, gels, and ointments. Pharmaceutically acceptable carriers also include, but are not limited to, saline and electrolyte solutions; ionic and nonionic penetrants such as sodium chloride, potassium chloride, glycerol and glucose; pH adjusters and buffers such as hydroxides, phosphates, citrates, acetates, borates, and triethanolamine; antioxidants such as hydrogen sulfite, sulfurous acid, metabisulfite, thiosulfurous acid, ascorbic acid, acetylcysteine, cysteine, glutathione, butylated hydroxyanisole, butylated hydroxytoluene, tocopherol and ascorbyl palmitate and salts thereof; surfactants such as phosphatidylcholine, phospholipids including but not limited to phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, and the like; polysorbate such as poloxamer and poloxamine, polysorbate 80, polysorbate 60 and polysorbate 20, and polyethers such as polyethylene glycol and polypropylene glycol; polyvinyl alcohol such as polyvinyl alcohol and povidone; cellulose derivatives such as methyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose and hydroxypropyl methyl cellulose and salts thereof; petroleum derivatives such as mineral oil and white petrolatum; fats such as lanolin, peanut oil, palm oil, soybean oil; mono-, di-and tri-glycerides; acrylic polymers such as carboxymethyl gel and hydrophobically modified crosslinked acrylate copolymers; polysaccharides, such as dextran and glycosaminoglycans, such as sodium hyaluronate. Such pharmaceutically acceptable carriers may be preserved with well known preservatives to prevent bacterial contamination, including but not limited to benzalkonium chloride, ethylenediamine tetraacetic acid and its salts, benzethonium chloride, chlorhexidine, chlorobutanol, methyl parahydroxybenzoic acid, thimerosal, and phenethyl alcohol, or may be non-preserved formulations for one or more uses.

For example, a tablet formulation or capsule containing compound I may contain other excipients that are not biologically active and that are not reactive with the active compound. Excipients for tablets may include fillers, binders, lubricants and glidants, disintegrants, wetting agents and release rate modifiers. The binder promotes the adhesion of the formulation particles and is very important for tablet formulations. Binders include, but are not limited to, carboxymethyl cellulose, ethyl cellulose, hydroxypropyl methylcellulose, methyl cellulose, karaya gum, starch, baical skullcap gum, poly (acrylic acid), and polyvinylpyrrolidone.

In another embodiment, the composition is a tablet.

In one embodiment, the tablet formulation comprises an ASD of the present invention in a weight range of 10-75%, preferably 20-60% or 45-55%.

In one embodiment, the tablet formulation comprises one or more fillers, such as lactose and/or microcrystalline cellulose, in a total weight percentage range of 10-80%, preferably 20-70% or 30-60%.

In one embodiment, the tablet formulation includes a disintegrant in a weight percent of 4 to 10%, preferably 4 to 9%, more preferably 5 to 7%.

In one embodiment, the tablet formulation includes a lubricant, such as magnesium stearate, in a weight percent range of 0.25 to 2.0%, preferably 0.25 to 1.0%, more preferably 0.25 to 0.75%.

The following examples further illustrate the invention. These examples are given solely for the purpose of illustration and are not to be construed as limiting.

Examples

EXAMPLE 1 preparation of form A

The starting compound I was prepared according to the procedure described in example 3 of WO 2015/048662. The starting compound I was dissolved in dichloromethane, and then ethyl acetate was added dropwise with stirring until a solid precipitated. The resulting solid was isolated by filtration and washed with ethyl acetate to give form a.

EXAMPLE 2 preparation of form F

100.1mg of form A was added to 2.5ml of acetonitrile, and the resulting mixture was stirred at room temperature for 20 days. And (5) centrifugally drying to obtain the crystal form F.

EXAMPLE 3 preparation of ASD (20% drug loading) by spray drying Dispersion

2.02g of Compound I are dissolved in 270ml of methanol at room temperature. While stirring at 100 rpm, 8.00g HPMC-AS (AS-MF) was slowly added. After the addition was complete, stirring was continued for 3-4h until a clear solution was obtained. The solution was then placed in a Yamato ADL 311SA spray dryer to produce ASD with an inlet temperature of 80 ℃, an outlet temperature of 50-54 ℃, a flow rate of 7-8ml/min and a spray air pressure of 0.1 megapascals. The collected spray-dried material was transferred to a glass dish, wrapped and dried under vacuum overnight to give 5.64g of ASD powder.

Example 4 preparation of ASD by Hot melt extrusion (20% drug load)

2.40g of Compound I and 9.60g of PVP-VA were mixed homogeneously. After sieving through a 40 mesh screen, the mixture was fed into a Thermo MiniCTW extruder at 150-160℃and 30 rpm for ASD preparation. The collected yellow solid was ground and passed through a 40 mesh screen to give 5.50g of ASD powder.

EXAMPLE 5 dissolution behavior of forms A, F and ASD

In a 50-ml centrifuge tube, accurately weighed 10mg of each of the type A and type F samples, and 50mg of HPMCAS-20-SDD (20% drug loading ASD prepared by spray drying, see example 3) were added to 20ml of fasted simulated intestinal fluid (FaSSIF) (pH 6.5). The test tube was placed in a shaker and shaken at 37℃and 100 revolutions per minute. At various time points (10, 30, 60, 120, 240 minutes) 350. Mu.l of suspension were taken and centrifuged at 13000 rpm for 3 minutes to give a clear solution which was then analyzed by HPLC. The results (average of three replicates) are shown in figure 1. The results show that ASD dissolves significantly better in FaSSIF than in form A, which in turn dissolves better than in form F.

EXAMPLE 6 glass transition temperature

Precisely weighed samples (containing 5mg of compound I, see table 3) were prepared as in examples 3 and 4, and containing different amounts of polymer and drug. These samples were placed in DSC pans (TA instruments) respectively, then sealed and placed in TA instrument Q2000. The pot was heated at 105 ℃ for 3 minutes and then cooled rapidly to 0 ℃ within 1 minute. DSC analysis is carried out at a rate of 10 ℃/min between 0 and 180 ℃. The glass transition temperatures (Tg) are summarized in table 3.

TABLE 3 Table 3

Sample of	Polymer	ASD preparation method	Drug loading (%)	Tg(℃)
					A type	-		100	69.4
HPMCAS-20-SDD	HPMC-AS	Spray drying	20	83.5
					HPMCAS-40-SDD	HPMC-AS	Spray drying	40	72.6
HPMCAS-60-SDD	HPMC-AS	Spray drying	60	69.6
					PVPVA-20-HME	PVP-VA	Hot melt extrusion	20	96.4
PVPVA-40-HME	PVP-VA	Hot melt extrusion	40	86.6
					PVPVA-50-HME	PVP-VA	Hot melt extrusion	60	86.5

The DSC curve shows only one glass transition temperature, and no melting peak is observed, indicating that compound I is in an amorphous state in the solid dispersions prepared by both techniques. As drug loading increases from 20% to 60%, tg decreases and the risk of phase separation increases. It is therefore desirable to maintain a low drug load to ensure physical stability.

The XRPD of HPMCAS-20-SDD is shown in FIG. 2.

EXAMPLE 7 elution of ASD with different polymers and different drug loadings

Dissolution of HPMCAS-20-SDD, HPMCAS-40-SDD, HPMCAS-60-SDD, PVPVA-20-HME samples was examined according to the protocol of example 5. The results are shown in FIG. 3.

The results showed that SDD with 20% and 40% drug loading had better dissolution than SDD with 60% drug loading. The solubility of all three SDDs was better than the 20% drug load ASD prepared from HME.

EXAMPLE 8 in vivo PK

3 fed female Sprague-Dawley rats were orally administered 10 ml of a 0.5% methylcellulose suspension containing SDD at a dose of 30mg/kg to evaluate the pharmacokinetics of HPMCAS-20-SDD and HPMCAS-40-SDD. Blood samples were taken at 0.25, 0.5, 1,2, 4, 8 and 24 hours post-dose. The concentration of compound I was quantitatively analyzed by LC-MS/MS using an API-4500 mass spectrometer. The limit of plasma quantification (LOQ) was 2ng/ml. PK parameters were calculated with WinNonlin. The results are summarized in Table 4 and FIG. 4. The results indicated that SDD at 20% and 40% drug loading had comparable in vivo exposure.

TABLE 4 Table 4

EXAMPLE 9 stability assessment of ASD

Each brown glass vial containing ASD samples (A, PVPVA-20-HME; B, HMPCAS-20-SDD; C, HMPCAS-40-SDD; D, HMPCAS-60-SDD) was placed in a desiccator, either open or closed. Some dryers were bottom loaded with a saturated potassium bromide solution to maintain 60% Relative Humidity (RH), while others were bottom loaded with a saturated sodium chloride solution to maintain 75% relative humidity. The dryer is then stored in a temperature-controlled drying oven at 25 ℃ or 40 ℃. After 7-58 days, samples were evaluated for XRPD, DSC and dissolution.

XRPD results

Fig. 5 is an XRD pattern of ASD after one week of storage under different conditions: (a) PVPVA-20-HME; (B) HMPCAS-20-SDD; (C) HMPCAS-40-SDD; (D) HMPCAS-60-SDD.

XRPD of form a is also shown in figure 5. The results showed that none of the ASD samples showed a crystalline form peak after one week of storage under different conditions, indicating that all four ASD samples remained amorphous for at least one week.

DSC results

HMPCAS-20-SDD was tested for 25 ℃/60% RH opening at (A); (B) 25 ℃/60% rh containment; (C) DSC curves were stored for 0-58 days at 40℃under 75% RH seal. The results showed only one Tg without an additional melting peak, indicating that the ASD remained amorphous for 58 days under three different storage conditions.

PVPVA-20-HME opening at (A) 25 ℃/60% RH was tested; (B) 25 ℃/60% rh containment; (C) DSC curves were stored for 0-14 days at 40℃under 75% RH seal. No additional melting peaks appeared within two weeks under different storage conditions. Therefore, ASD is relatively stable.

Dissolution results

FIG. 6 is a graph of HMPCAS-20-SDD opening at (A) 25 ℃/60% RH; (B) 25 ℃/60% rh containment; (C) Dissolution profile in FaSSIF after storage for 0-58 days at 40 ℃/75% rh in a closed condition.

HMPCAS-20-SDD was tested for 25 ℃/60% RH opening at (A); (B) 25 ℃/60% rh containment; (C) Dissolution profile at 40 ℃/75% rh in close confinement for different storage times (0, 7, 14, 28 and 56 days). The results are summarized in fig. 6. The results show no significant change in ASD dissolution after 8 weeks of storage at 25℃/60% RH. However, after 8 weeks of storage at 40 ℃/75% rh seal, dissolution was significantly reduced.

In addition, PVPVA-20-HME was also tested for opening at (A) 25 ℃/60% RH; (B) 25 ℃/60% rh containment; (C) Dissolution profile at 40 ℃/75% rh in close condition for different storage times (0, 7 and 14 days). The results showed no significant change in ASD dissolution after 2 weeks of storage at 25 ℃/60% rh.

EXAMPLE 10 tablet formulation

A raw tablet consisting of HMPCAS-20-SDD and some common excipients such as microcrystalline cellulose, croscarmellose sodium and sodium stearate was prepared for evaluation of dissolution behavior and stability as shown in table 5.

TABLE 5 tablet formulation examples containing 100mg of Compound I per tablet

Dissolution evaluation

The closed brown glass vials containing the tablets of table 5 were placed in a desiccator with a saturated potassium bromide solution in the bottom portion to maintain 60% Relative Humidity (RH) and the desiccator was stored in a temperature controlled desiccator at 25 ℃. One month later, a piece was taken and added to 500 ml of PBS buffer (pH 6.5) containing 0.1% Tween 80, followed by stirring at 37℃at 75 rpm. At various time points (10, 30, 60, 120, 240 minutes) 2ml of liquid were taken and filtered with a 0.45um filter membrane and the filtrate was analyzed by HPLC. The results (average of three replicates) are shown in fig. 7. After 1 month of storage at 25 ℃/60% RH under sealing, there was no significant change in dissolution of the test pieces.

Claims (5)

1. An amorphous solid dispersion comprising 20-40% w/w of compound I or a pharmaceutically acceptable salt thereof, and 60-80% w/w of hydroxypropyl methylcellulose acetate succinate (HPMC-AS), wherein the amorphous solid dispersion is prepared by spray drying,

a compound I.

2. The amorphous solid dispersion according to claim 1, containing 20% w/w or 40% w/w of compound I.

3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the amorphous solid dispersion of claim 1.

4. A pharmaceutical composition according to claim 3, in the form of a tablet or capsule.

5.A method of preparing the amorphous solid dispersion of claim 1, comprising the steps of:

(a) Dissolving a compound I or pharmaceutically acceptable salt thereof and HPMC-AS in an organic solvent to obtain a solution; a kind of electronic device with high-pressure air-conditioning system

(b) The solution is spray dried to obtain the amorphous solid dispersion.